References
1. Pérez C, Margarit C, Sánchez-Magro I, de Antonio A, Villoria J. Chronic Pain Features Relate to Quality of Life More than Physiopathology: A Cross-Sectional Evaluation in Pain Clinics. Pain Pract. 2017;17(7):866-78. DOI: 10.1111/papr.12533.
2. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19. DOI: 10.1016/S1474-4422(10)70143-5.
3. Pérez C, Ribera MV, Gálvez R, Micó JA, Barutell C, Failde I, et al. High prevalence of confirmed, but also of potential and believed, neuropathic pain in pain clinics. Eur J Pain. 2013;17(3):347-56. DOI: 10.1002/j.1532-2149.2012.00204.x
4. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. DOI: 10.1038/nrdp.2017.2.
5. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73. DOI: 10.1016/S1474-4422(14)70251-0.
6. Binder A, Baron R. The Pharmacological Therapy of Chronic Neuropathic Pain. Dtsch Arztebl Int. 2016;113(37):616-25. DOI: 10.3238/arztebl.2016.0616.
7. Pérez C, Navarro A, Saldaña MT, Wilson K, Rejas J. Modeling the predictive value of pain intensity on costs and resources utilization in patients with peripheral neuropathic pain. Clin J Pain. 2015;31(3):273-9. DOI: 10.1097/AJP.0000000000000110.
8. Gonçalves Dos Santos G, Delay L, Yaksh TL, Corr M. Neuraxial Cytokines in Pain States. Front Immunol. 2020;10:3061. DOI: 10.3389/fimmu.2019.03061.
9. Cook AD, Christensen AD, Tewari D, McMahon SB, Hamilton JA. Immune Cytokines and Their Receptors in Inflammatory Pain. Trends Immunol. 2018;39(3):240-55. DOI: 10.1016/j.it.2017.12.003.
10. Skaper SD, Facci L, Zusso M, Giusti P. Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons. Neuroscientist. 2017;23(5):478-98. DOI: 10.1177/1073858416687249.
11. Cairns BE, Arendt-Nielsen L, Sacerdote P. Perspectives in Pain Research 2014: Neuroinflammation and glial cell activation: The cause of transition from acute to chronic pain? Scand J Pain. 2015;6(1):3-6. DOI: 10.1016/j.sjpain.2014.10.002.
12. Zajaczkowska R, Kwiatkowski K, Pawlik K, Piotrowska A, Rojewska E, Makuch W, et al. Metamizole relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model of neuropathic pain. Pharmacol Rep. 2020;10.1007/s43440-020-00137-8. DOI: 10.1007/s43440-020-00137-8.
13. Nassini R, Fusi C, Materazzi S, Coppi E, Tuccinardi T, Marone IM, et al. The TRPA1 channel mediates the analgesic action of dipyrone and pyrazolone derivatives. Br J Pharmacol. 2015;172(13):3397-411. DOI: 10.1111/bph.13129.
14. Babej-Dölle R, Freytag S, Eckmeyer J, Zerle G, Schinzel S, Schmeider G, et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study. Int J Clin Pharmacol Ther. 1994;32(4):204-9. Zhang W, Yu T, Cui X, Yu H, Li X. Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA-101 expression and the E2F2/TLR4/NF-κB. Exp Physiol. 2020;10.1113/EP088596. DOI: 10.1113/EP088596.